3-antigen Hepatitis B Vaccine Available for Adults in the Belgium and Netherlands

VBI Vaccines Inc. today announced that the PreHevbri® vaccine is now available in the Netherlands and Belgium for active immunization against infection caused by all known subtypes of the hepatitis B virus (HBV) in adults.

It is the only approved 3-antigen hepatitis B vaccine for adults in the Netherlands and Belgium.

As part of the partnership announced in September 2022, PreHevbri is available through France-based Valneva SE's commercial infrastructure and distribution networks.

PreHevbri (PreHevbrio™, Sci-B-Vac®) can be expected that hepatitis D will also be prevented by immunization with PreHevbri as hepatitis D does not occur without hepatitis B infection.

Jeff Baxter, President and CEO of VBI, commented in a press release on July 19, 2023, "Over the next several months, we expect to continue to expand global access to PreHevbri with additional market launches as we work to make an impact in the fight against hepatitis B worldwide."

This HBV vaccine is currently available in the U.S., Europe, the U.K., and Israel. 

Hepatitis B is one of the world's most significant infectious disease threats, with more than 290 million people infected globally. It is the leading cause of liver disease, about 25%, and is tough to cure, says the U.S. CDC.

Furthermore, women with hepatitis B can transmit the virus to their newborns during birth. If not vaccinated, 90% of infants infected with HBV at birth will progress to chronic HBV infections.